ADMA Biologics
ADMA
322 hedge funds and large institutions have $1.7B invested in ADMA Biologics in 2026 Q2 according to their latest regulatory filings, with 51 funds opening new positions, 90 increasing their positions, 148 reducing their positions, and 84 closing their positions.
95% more call options, than puts
Call options by funds: $27.9M | Put options by funds: $14.3M
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
1.28% less ownership
Funds ownership: 88.99% → 87.71% (-1.3%)
10% less funds holding
Funds holding: 357 → 322 (-35)
11% less capital invested
Capital invested by funds: $1.91B → $1.7B (-$210M)
39% less repeat investments, than reductions
Existing positions increased: 90 | Existing positions reduced: 148
39% less first-time investments, than exits
New positions opened: 51 | Existing positions closed: 84
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$68.6M |
| 2 |
First Trust Advisors
Wheaton,
Illinois
|
+$67.8M |
| 3 |
D.E. Shaw & Co
New York
|
+$43M |
| 4 |
State Street
Boston,
Massachusetts
|
+$27.6M |
| 5 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$21.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
American Century Companies
Kansas City,
Missouri
|
-$41.6M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$40.5M |
| 3 |
Invesco
Atlanta,
Georgia
|
-$32.6M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$26.2M |
| 5 |
Nuveen
Charlotte,
North Carolina
|
-$25.9M |
ADMA Hedge Fund Activity: Q2 2026 in Review
322 of the 8,349 institutional investors tracked by Wall St. Rank reported a position in ADMA Biologics (ADMA) for Q2 2026, worth a combined $1.7B — down 11% from $1.91B a quarter earlier.
Sellers outnumbered buyers: 84 funds closed out of ADMA and 51 opened new positions — a net loss of 33 holders — while 148 trimmed existing stakes and 90 added.
The largest buyer was Rubric Capital Management (New York), adding an estimated $68.6M. The largest seller was American Century Companies, cutting an estimated $41.6M.
- 322 institutional investors held ADMA Biologics (ADMA) as of Q2 2026, down from 357 in Q1 2026.
- Funds reported $1.7B of ADMA Biologics stock for Q2 2026, down 11% quarter-over-quarter.
- 51 funds opened new ADMA Biologics positions in Q2 2026 and 84 closed out, a net change of -33 holders.
- The largest ADMA Biologics buyer in Q2 2026 was Rubric Capital Management (New York), an estimated $68.6M added.
- The largest ADMA Biologics seller in Q2 2026 was American Century Companies, an estimated $41.6M sold.
Based on aggregated 13F filings for Q2 2026.